ONCT — Oncternal Therapeutics Share News
0.000.00%
Last trade - 00:00- $1.56m
- -$13.02m
- $0.79m
Brief: Oncternal Therapeutics Inc - Estimates Cash And Cash Equivalents Were $63.7 Million As Of December 31, 2022
Brief: Oncternal Therapeutics Announces Appointment Of Jill Desimone To Board
U.S. STOCKS ON THE MOVE-Natural gas, Box Inc, Weber
Oncternal Therapeutics up as combination therapy for cancer shows promise
Brief: Oncternal Therapeutics Presents Updated Interim Data For Zilovertamab In Combination With Ibrutinib
Oncternal Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Oncternal Therapeutics To Present Updated Interim Phase 1/2 Data For Zilovertamab In Combination With Ibrutinib
Oncternal Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Oncternal Therapeutics To Provide Business Update And Report Third Quarter 2022 Financial Results
Oncternal gains on approval to start blood cancer therapy trial
Advisory: Stock alert on Oncternal Therapeutics withdrawn
Oncternal rises as FDA permits human trials of blood-cancer treatment
Brief: Oncternal Therapeutics Receives IND Clearance For Drug Candidate Onct-808
Oncternal edges up as late-stage trial of cancer drug begins
Brief: Oncternal Therapeutics Initiates Global Registrational Phase 3 Study Of Zilovertamab For Patients With MCL
Oncternal Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Oncternal Therapeutics Reports Qtrly Loss Per Share $0.23
Brief: Oncternal Therapeutics Reports Clinical Trial Collaboration
Brief: Oncternal Therapeutics Presents Plans For Registrational Phase 3 Study Evaluating Zilovertamab In Combination With Ibrutinib